WO2000037496A1 - Novel fibronectin-binding protein - Google Patents

Novel fibronectin-binding protein Download PDF

Info

Publication number
WO2000037496A1
WO2000037496A1 PCT/SE1999/002448 SE9902448W WO0037496A1 WO 2000037496 A1 WO2000037496 A1 WO 2000037496A1 SE 9902448 W SE9902448 W SE 9902448W WO 0037496 A1 WO0037496 A1 WO 0037496A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
fragment
binding
equi
sfs
Prior art date
Application number
PCT/SE1999/002448
Other languages
French (fr)
Inventor
Bengt Guss
Hans Lindmark
Karin Jacobsson
Lars Frykberg
Original Assignee
Bengt Guss
Hans Lindmark
Karin Jacobsson
Lars Frykberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bengt Guss, Hans Lindmark, Karin Jacobsson, Lars Frykberg filed Critical Bengt Guss
Priority to EP99964919A priority Critical patent/EP1151003A1/en
Priority to AU30947/00A priority patent/AU3094700A/en
Priority to CA002355831A priority patent/CA2355831A1/en
Publication of WO2000037496A1 publication Critical patent/WO2000037496A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • the present invention is generally related to a novel protein, methods to produce said protein and use thereof, e. g. for immunization purposes.
  • the present invention is related to a novel fibronectin-binding protein derived from a bacterium belonging to the genus Streptococcus, to a DNA sequence encoding said protein, recombinant DNA methods for the production of said protein, and use of said protein per se or a fragment thereof as an immunogenic protein or antigenic polypeptide or peptide, e. g. for use as an active component in a vaccine, or to produce antisera.
  • Streptococcal infections in horses are mainly caused by the species Streptococcus equi, which is classified as a Lancefield Group C Streptococcus and comprises two subspecies designated equi and zooepidemicus, respectively.
  • Streptococcus equi subsp. equi which is virtually confined to horses is the causative agent of strangles, a world-wide distributed and serious disease ofthe equine upper respiratory tract. Since strangles is a highly contagious disease, not only infected animals but also all other members of an afflicted stud must be isolated for as long as up to three months.
  • S. equi subsp. zooepidemicus is considered as an opportunistic commensal often occurring in the upper respiratory tract of healthy horses. However, after stress or virus infection, it can cause a secondary infection, which results in strangles-like symptoms. Moreover, subsp. zooepidemicus infects not only horses but also a wide range of other animals, like pigs, dogs, cats, and cows. Even human cases with infection due to subsp. zooepidemicus have been reported. This subspecies has been implicated as the primary pathogen in conditions such as endometritis, cervicitis, abortion, mastitis, pneumonia, abscesses and joint infections.
  • antibiotics such as penicillin, tetracycline or gentamicin
  • an effective prophylactic agent that could prevent outbursts of such infections and obviate or reduce the risk for development of resistant strains associated with antibiotic treatment, would be appreciated.
  • Fn fibronectin
  • Fn-binding proteins from different streptococcal species have been cloned and sequenced previously.
  • S. equi one Fn-binding protein has been cloned and characterized earlier, which is a Fn-binding cell-surface protein of subsp. zooepidemicus, that has been designated FNZ (9).
  • FNZ Fn-binding cell-surface protein of subsp. zooepidemicus
  • the present invention is based on this novel protein originally derived from S. equi subsp. equi and its potential use for immunization purposes.
  • the present invention is directed to a protein having an amino acid sequence encoded by a nucleic acid sequence or gene, that forms a portion of the genome of S. equi subsp. equi, and which protein binds specifically to mammalian fibronectin.
  • the present invention is also directed to an isolated protein, specifically binding to fibronectin, such as mammalian, and specifically equine, fibronectin, and having an amino acid sequence as shown in SEQ. ID. NO. 1.
  • the present invention is generally concerned with analogs or fragments of the present protein having fibronectin-binding properties.
  • a suitable fragment is comprised ofthe sequence ofthe present protein, that lacks the N-terminal signal sequence of the preprotein.
  • a further suitable fragment ofthe present protein lacks a portion of said amino acid sequence, said portion comprising an amino acid sequence binding to a collagen-binding domain of fibronectin.
  • the present invention is also concerned with methods to produce the present protein, analogs or fragments thereof, which methods are based on DNA technology; and with nucleic acid sequences, and more specifically DNA sequences or fragments, intended for use in ' such methods, as well as use of said protein, analogs or fragments thereof for therapeutic purposes, such as immunizing purposes.
  • SFS novel protein
  • sfs novel gene
  • Fig. 1(A) shows a map of a clone designated pSFS62 with the gene sfs indicated.
  • Fig. 1 (B) shows a schematic presentation of protein SFS with the functional domains indicated.
  • the bars correspond to the amino acid sequences of phagemid clones isolated by panning against Fn (S1-S4).
  • Figures refer to the amino acid positions in protein SFS as shown in SEQ. ID. NO. 1 and the figures within brackets indicate the number of identical clones, that were isolated and sequenced.
  • Fig. 2 shows the results of Southern blot analysis of chromosomal DNA from ten streptococcal isolates.
  • the DNA was digested by Apal and separated by pulsed-field gel electrophoresis in duplicate.
  • the radioactively labeled probe used corresponds to the gene sfs.
  • Fig. 3 shows the results from inhibition assays related to Fn-binding.
  • Cells of subsp. zooepidemicus ZV, subsp. zooepidemicus DSM 20727, subsp. equi Bd3221, and subsp. equi 640 were incubated with iodine-labeled Fn (hatched bars) and with a mixture of iodine- labeled Fn and protein SFS-E (striped bars). The bars represent means of duplicates and the standard deviation is indicated.
  • Fig. 4 shows the results from inhibition assays related to inhibition of binding between collagen and Fn with protein SFS.
  • Collagen type I coated micro titer wells were incubated with Fn and a two-fold serial dilution of SFS. Bound Fn was detected by antibodies as described in Example 3. Points represent means of duplicates and the standard deviation is indicated.
  • the present invention is directed to a fibronectin-binding (hereinafter abbreviated Fn-binding) protein, which has an amino acid sequence that can be expressed from a nucleic acid coding sequence, that can be isolated from and forms a portion ofthe genomes of S. equi, for instance subsp. equi.
  • Fn-binding fibronectin-binding
  • the present invention is directed to an isolated protein, specifically binding to fibronectin and having an amino acid sequence as shown in SEQ. ID. NO. 1 below, or a fragment or analog thereof.
  • the present invention is also related to proteins or polypeptides having an amino acid sequence as shown in SEQ. ID. NO. 1 containing deletions or substitutions of amino acids, such as fragments and analogs ofthe present protein having fibronectin-binding properties, suitably conserved, or specifically designed, Fn-binding properties.
  • One such fragment or analog is comprised ofthe mature protein lacking the N-terminal amino acids no. 1 to 29 inclusive.
  • Other fragments have en amino acid sequence corresponding to a portion ofthe amino acid sequence as shown in SEQ. ID. NO. 1 comprising a fibronectin-binding domain or an antigenic determinant or epitope.
  • Still other fragments have an amino acid sequence corresponding to a portion ofthe sequence as shown in SEQ. ID. NO. 1, wherein an amino acid sequence binding to a collagen-binding domain of fibronectin (Fn) and comprising the amino acids QGERGEAGPP, is deleted.
  • a further embodiment is concerned with a protein of the present invention having an amino acid composition of approximately 53 glycine residues, 39 serine residues and 38 proline residues evenly distributed in the protein and optionally 13 tyrosine residues in the C- terminal part ofthe protein.
  • the present invention is concerned with a wild-type ptotein encoded by S. equi, that can be isolated and purified when recovered from said organism, as well as with a recombinant SFS protein as discussed above, said proteins having Fn-binding properties.
  • the present invention is also concerned with a nucleic acid sequence encoding the SFS protein or fragments or analogs thereof.
  • this sequence is a DNA sequence and contains an SFS coding sequence, such as the entire sfs gene, or a portion thereof encoding the SFS protein or a fragment or analog therof.
  • one embodiment of the present invention is related to a DNA sequence having a nucleotide sequence as shown in SEQ, ID. NO. 2 or to an equivalent thereof.
  • GGTCATCACC ATCAGCCACA AGATCTAGGT AAGGATAATT CTAGCCCGCA GCCTCAACCA 420
  • the present invention is also related DNA sequences having nucleotide substitutions, that do not change the encoded product or interfere with its expression. This is due to the well-known redundancy of the genetic code, i. e. more than one coding nucleotide triplet (codon) can code for or define a particular amino acid residue or a function, such as a stop codon function, etc.. Thus, such functionally equivalent sequences are also encompassed by the present invention. Such equivalents may also arise due to spontaneous mutations.
  • the above DNA sequence when used to produce the present protein, such as a protein having the amino acid sequence shown in SEQ. ID. NO. 1, with methods based on recombinant DNA technology, the above DNA sequence may be modified to adapt to the codon frequency of the host organism used to produce the present protein, or fragments or analogs thereof.
  • the present invention is also concerned with a host cell comprising a DNA fragment or sequence of the present invention, e. g. a eukaryotic or, suitably, a prokaryotic host cell.
  • a suitable prokaryotic host cell is derived from different strains of E. coli.
  • the present invention is concerned with a method to produce the present protein, fragments or analogs thereof comprising culturing a host cell containing the DNA sequence of the present invention, and isolating the expressed protein from the culture.
  • this method also comprises purification of the expression product, such as affinity chromatography purification, conveniently based on use of "affinity tails".
  • a suitable method comprises
  • step (c) culturing the host cell provided in step (b) under conditions required for expression ofthe product encoded by said DNA fragment;
  • said method further comprises a step (e), wherein the isolated product from step (d) is purified, e. g. by affinity chromatography, such as Fn-aff ⁇ nity chromatography, or with the use of "affinity tails" as is well-known in this field of art.
  • affinity chromatography such as Fn-aff ⁇ nity chromatography
  • the present invention is further concerned with a vaccine comprising the present Fn- binding protein or a fragment or an analog thereof as an antigenic or immunogenic component.
  • This vaccine is intended for use as a vaccine protecting against infection with any one ofthe two subspecies equi and zooepidemicus of S. equi.
  • a further embodiment ofthe present invention is concerned with a vaccine as defined above, that protects horses against strangles caused by S. equi subsp. equi infection.
  • a vaccine could protect also against infection with subsp. zooepidemicus.
  • the vaccine ofthe present invention is suitably a subunit vaccine.
  • the vaccine may be comprised of a cocktail of antigenic and /and or immunogenic components comprising the present protein or an analog or a fragment thereof as one such component.
  • the present invention is also concerned with use ofthe present Fn-binding protein, analogs or fragments thereof in the preparation of a vaccine protecting against S. equi, for instance a vaccine as disclosed above. Furthermore, the present invention is also concerned with the production of antibodies raised against the present protein , analogs or fragments thereof, with fragments of such antibodies and with the production of antisera. Antibodies and/or antisera could be produced by in vivo administration, e. g. injection, of an antigen comprising the said protein, an analog or a fragment thereof, to a host to elicit an immune response in said host, and recovering antiserum thereby produced in said host and, optionally, recovering or isolating antibodies contained in said antiserum or in other body fluids from said host. Not only polyclonal but also monoclonal antibodies could be produced in accordance with well-known methods. EXPERIMENTAL PART
  • the plasmid pUC 19 was used for cloning purposes and pGEX- 5X-2 (Pharmacia Biotech, Uppsala, Sweden) for facilitating purification of proteins.
  • Phagemid pG8SAET (19) was used for purification of protein SFS and for construction ofthe phage display library.
  • Streptococcal strains were grown on horse blood agar plates or in Todd- Hewitt broth (Oxoid, Basingstoke, UK) supplemented with 0.5% yeast extract (THY).
  • E. coli strains were cultured in Luria-Bertani (LB) medium supplemented in appropriate cases with 50 ⁇ g of ampicillin per ml.
  • isolates of S. equi it is known that isolates of subsp. equi are serologically and genetically very homogeneous whereas isolates of subsp. zooepidemicus display a high degree of heterogeneity (2, 8, 10, 13).
  • Example 1 Cloning and isolation of a gene sfs encoding the Fn-binding protein SFS.
  • A. Construction of a phagemid library A shotgun phage display library was constructed from subsp. equi Bd 3221 essentially as described by Jacobsson and Frykberg (6). Briefly, chromosomal DNA of this strain was isolated as described earlier (9) and subsequently purified and fragmented by sonication.
  • the obtained fragments were treated with T4 DNA polymerase to generate blunt ends and subsequently ligated into S « ⁇ BI-digested and dephosphorylated pG8SAET vector. Approximately 4.5 x 10 6 ampicillin-resistant transformants were obtained after electrotransformation of the ligated material into E. coli, TGI cells.
  • This library was used in the following Section B, wherein phage particles containing inserts related to Fn-binding properties are identified.
  • Cells from one filter were lysed using chloroform vapor and after blocking the filter with PBS-T supplemented with casein (O.lmg/ml), it was incubated with human Fn (l ⁇ g/ml; Sigma) for 2 h, and after washing, a rabbit anti-Fn antibody (diluted 1/1000; Sigma) was added. After 1 h of incubation and washing, the filter was incubated for additional 1 h with a HRP-labeled secondary antibody (diluted 1/1000; Bio-Rad, Richmond, Calif). Reactive bands were visualized by using 4-chloro-l-naphthol (Serva, Heidelberg, Germany).
  • the second filter was subjected to colony hybridization essentially as described in Sambrook et al. (22) with use of a radioactively labeled probe that covered the entire fnz gene and was generated by PCR amplification of chromosomal DNA from subsp. zooepidemicus strain ZV using the primers:
  • This clone, pSFS62 had an open reading frame of 1,035 bp, from which the phagemid sequences were found to originate (Figs. 1 and SEQ. ID. NO. 2).
  • the open reading frame is preceded by sequences typical for promoter and ribosome-binding sites (not shown) and is followed by sequences (not shown) resembling a transcriptional termination, suggesting that the gene is translated from a monocistronic messenger.
  • the SFS-coding nucleotide sequence ofthe sfs gene is shown in SEQ. ID. NO. 2.
  • Southern blots The Southern blot analysis referred to above and further below, was performed according to the following. Agarose imbedded chromosomal DNA digested with Apal was resolved on 1.2% SeaKem GTG agarose gel (FMC, Rockland, ME) in 0.5 x TBE buffer by PFGE using a Gene Navigator (Pharmacia Biotech, Uppsala, Sweden) as earlier described (10). The DNA was transferred to nylon filters (Hybond-N+, Amersham) by vacuum blotting (VacuGene XL, Pharmacia Biotech) in accordance with the manufacturer's protocol.
  • the filters were prehybridized for 2 h at 65 °C in 6 x SSC, 3 x Denhardt's solution, and 0.5% SDS and subsequently incubated with the radioactively labeled sfs probe overnight, using the same conditions.
  • the membranes were washed 3 x 20 min at 65°C with 0.2 x SSC, 0.1% SDS and subjected to autoradiography.
  • the probe sfs was generated by PCR amplification of chromosomal DNA from subsp. equi Bd 3221 using the primers: fs5, 5'-ACAAGCCATGGAGCACTTGTCTTTGGAGGT and fr4, 5 ' -GTCGGGATTGTAAGAATAGCC.
  • the single band obtained after agarose gel electrophoresis was purified and random- primed.
  • Example 2 Construction and purification of SFS as a fusion protein.
  • This vector encodes a 13 amino acid peptide tag (E-tag) which facilitates the purification ofthe recombinant protein using a HiTrap Anti-E tag column (Pharmacia Biotech).
  • the recombinant protein SFS-E was purified from the periplasmic space according to the manufacturer's protocol. After cleaving from the E-tag, the SFS protein was obtained having a calculated molecular mass of 40 kDa.
  • the charged amino acids followed by a stretch of hydrophobic residues in the N-terminal end of the protein, indicate a signal sequence and by the method of von Heijne (14) a possible signal sequence cleavage site was found between amino acids 29 and 30, resulting in a mature protein with a calculated molecular mass of 36 kDa.
  • the isolated Fn-binding phagemid clones contained inserts originating from the central part of the protein, where two repetitive sequences of 21 residues, called Rl and R2, resp., are situated (Fig. 1). Three amino acids were found to dominate the composition of protein SFS, 53 residues are glycines (14.4%), 39 serines (10.6%), and 38 prolines (10.3%). These three amino acids are evenly distributed in the protein in contrast to the 13 tyrosine residues which occur only in the C-terminal part ofthe protein. Protein SFS does not contain any sequence motifs known to mediate attachment to the bacterial cell-wall.
  • Example 3 Inhibition assays. Cells from overnight cultures of streptococci were collected by centrifugation, washed in PBS, and suspended in PBS-0.2% Tween 20 to an optical density at 600 nm of 0.2. In cases of inhibition, 25 nM of affinity purified fusion- protein SFS-E was preincubated 15 min with 16 pM of 12D I-labeled human Fn (91,061 cpm) and thereafter bacteria (500 ⁇ l) were added. After two hours incubation at room temperature, the mixtures were centrifuged and the supernatants removed. The radioactivity associated with the pellets was quantified in a gamma counter (LKB Wallac, Turku, Finland). Radioactivity (808 cpm) recovered from a control (tubes that contained no streptococci) was subtracted from each test.
  • RNA was extracted from S. equi cells by using the Blue FastRNA kit (Bio 101, Vista, CA) according to the manufacturer's protocol. RNA concentration was determined spectrophotometrically and by visual estimation ofthe rRNA bands on an agarose gel. RNA (10 ⁇ g) was loaded on a formaldehyde-containing agarose gel. RNA was transferred by vacuum-blotting to a positively charged nylon filter (Hybond-N+, Amersham) and cross-linked. Further steps were performed as described for Southern blots above with the exception that ssDNA was added to the pre-hybridization and hybridization solutions. Example 5. The ability of SFS to inhibit the binding between collagen and Fn.
  • polystyrene 96-well microtiter plates were coated for one hour with collagen type I from calf skin (Boehringer, Mannheim, Germany) in PBS. The wells were blocked for one hour with PBS-T supplemented with casein (0.1 mg/ml) and then washed four times with PBS-T.
  • the fusion protein SFS-E was diluted in a two-fold serial and added to the wells together with 0.2 ng of Fn. After 2 h incubation, the wells were washed and a rabbit anti-Fn antibody was added and allowed to bind for 1 h. Finally, the wells were incubated for 1 h with a secondary HRP-labeled antibody.
  • the gene sfs is generally present in isolates of subsp. equi.
  • Southern blots performed as disclosed above revealed that a [ P] dATP-labeled probe, corresponding to the gene sfs, hybridized to all the 50 subsp. equi and to 41 out of 48 subsp. zooepidemicus isolates tested.
  • the results from the hybridization analysis are, for a selected number of strains, shown in Fig. 2. No significantly weak signal, that could not be explained by less chromosomal DNA on the gel, was detected for any ofthe positive S. equi isolates.
  • Protein SFS displays sequence similarity to both collagen and a potential cell- wall protein of S. pyogenes.
  • Collagen sequences gave highest scores when searching the database Swissprot for SFS-like sequences. The similarity was evenly distributed through protein SFS, and the main reason for the high score is the high content of glycine, serine, and proline, i. e. residues which are also common in collagen. However, a more pronounced similarity was seen for the Fn-binding domain of SFS against collagen.
  • a sequence comparison was also done against the Oklahoma S. pyogenes genomic sequence database, which at the time of search consisted of 98% ofthe S. pyogenes genome.
  • Protein SFS inhibits the binding between Fn and collagen.
  • the similarity between protein SFS and collagen suggested that these proteins might bind to the same site on the Fn molecule.
  • microtiter wells coated with collagen were incubated with a mixture of Fn and a serial dilution of protein SFS. Bound Fn was detected by an anti-Fn antibody and as seen in Fig. 4, protein SFS inhibits the binding in a concentration dependent way.
  • the previously known protein F ⁇ Z did not inhibit the binding between Fn and collagen (data not shown).
  • protein SFS did not inhibit the binding between the said protein FNZ and Fn, and the protein FNZ did not inhibit the binding between protein SFS and Fn.
  • Protein SFS does not bind collagen. This was tested in order to control that the inhibition of binding between Fn and collagen by protein SFS is dependent on the binding of protein SFS to Fn and not to collagen. Taken together this suggests that protein SFS and the previously known protein FNZ have clearly separate binding sites on the Fn molecule and that protein SFS binds to the 30-40 kDa collagen- binding domain of Fn.
  • Example 6 the potential use of the present protein as a vaccine is illustrated in a test wherein the immunogenic properties of the present novel protein are confirmed.
  • Example 6 Immunogenic properties of Protein SFS.
  • Affinity purified recombinant protein SFS (Example 2) was, under reducing conditions, subjected to SDS- PAGE on a precasted 8-25 % gradient-gel using the PHAST system (Pharmacia Biotech, Sweden). The molecular weight markers used were obtained from BioRad, CA, USA. After electrophoresis was completed, a nitrocellulose (NC) filter (Hybond C, Amersham, UK) previously soaked in PBS was put on the gel and the temperature raised to 45° C.
  • NC nitrocellulose
  • the NC-filter was wetted with 1 ml PBS, and removed and placed in 15 ml PBS-T containing casein (0.1 mg/ml) for 1 hour (with two changes of PBS-T casein solution) at room temperature under gentle agitation.
  • the gradient-gel was after transfer removed and stained with Coomassie-blue using the PHAST system.
  • the NC-filter was removed and incubated in 5 ml PBS-T casein solution containing 5 ⁇ l serum from a horse which previously had got the diagnosis strangles and found to be a carrier of S. equi. After 2 hours incubation at room temperature, under gentle agitation, the filter was extensively washed with PBS-T and incubated in 5 ml PBS-T casein solution containing rabbit anti horse antibodies (Nordic Immunology,
  • the filter was transferred to a solution containing a substrate for peroxidase (containing 25 ml PBS + 6ml 4-chloro-l-naphtol (Sigma, USA, 3 mg/ml in methanol) + 20 ⁇ l H 2 O 2 (35%). After about 15 minutes, the degree of color was measured by eye. The bands appearing on the NC-filter and the bands appearing on the corresponding Coomassie-blue stained PAGE were compared.
  • Protein F a fibronectin-binding protein, is an adhesin ofthe group A streptococcus Streptococcus pyogenes. Proc. Natl. Acad. Sci. USA 89:6172-6176.
  • nucleotide Sequence Accession Number The nucleotide sequence of gene (9) is available from the EMBL sequence data bank under accession number X99995. The complete gene sequence and the deduced amino acid sequence ofthe protein FNZ are shown below:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention is concerned with a novel fibronectin-binding protein of Streptococcus equi, to a DNA fragment encoding this protein, to host cells and vectors containing said DNA fragment and to methods to produce said protein based on recombinant DNA technology. The invention is also related to use of said protein in the preparation of a vaccine, to a vaccine containing said protein, to antibodies specific for said protein and to polyvalent antisera containing such antibodies.

Description

Novel fibronectin-binding protein
The present invention is generally related to a novel protein, methods to produce said protein and use thereof, e. g. for immunization purposes.
More specifically, the present invention is related to a novel fibronectin-binding protein derived from a bacterium belonging to the genus Streptococcus, to a DNA sequence encoding said protein, recombinant DNA methods for the production of said protein, and use of said protein per se or a fragment thereof as an immunogenic protein or antigenic polypeptide or peptide, e. g. for use as an active component in a vaccine, or to produce antisera.
Streptococcal infections in horses are mainly caused by the species Streptococcus equi, which is classified as a Lancefield Group C Streptococcus and comprises two subspecies designated equi and zooepidemicus, respectively. Streptococcus equi subsp. equi which is virtually confined to horses is the causative agent of strangles, a world-wide distributed and serious disease ofthe equine upper respiratory tract. Since strangles is a highly contagious disease, not only infected animals but also all other members of an afflicted stud must be isolated for as long as up to three months.
S. equi subsp. zooepidemicus, is considered as an opportunistic commensal often occurring in the upper respiratory tract of healthy horses. However, after stress or virus infection, it can cause a secondary infection, which results in strangles-like symptoms. Moreover, subsp. zooepidemicus infects not only horses but also a wide range of other animals, like pigs, dogs, cats, and cows. Even human cases with infection due to subsp. zooepidemicus have been reported. This subspecies has been implicated as the primary pathogen in conditions such as endometritis, cervicitis, abortion, mastitis, pneumonia, abscesses and joint infections.
Although it is possible to treat and cure these streptococcal infections with antibiotics, such as penicillin, tetracycline or gentamicin, an effective prophylactic agent, that could prevent outbursts of such infections and obviate or reduce the risk for development of resistant strains associated with antibiotic treatment, would be appreciated.
However, although many attempts have been made to develop prophylactic agents such as vaccines against S. equi, at the present time no efficient vaccines or immunizing preparations are available, neither for the subspecies equi nor for the subspecies zooepidemicus. Existing vaccines against strangles are based on inactivated, e. g. heat- killed, or attenuated strains of S. equi subsp. equi or acid extracts/mutanolysin enriched in M-protein(s), i. e. immunogenic protein(s) produced by S equi. A vaccine against S. equi subsp. zooepidemicus based on an M-like protein is disclosed in US-A-5 583 014. Since the previously developed vaccines or immunizing preparations are hampered by side-effects and, moreover, provide insufficient protection, there is a need for efficient prophylactic agents, such as vaccines, that protect against S. equi infections and/or prevent spread thereof.
It is well known that attachment to eukaryotic cell surfaces is an essential step in the establishment of infection and colonization by bacterial pathogens. Accordingly, streptococcal surface proteins, that interact with and/or bind to different components ofthe Extracellular Matrix (ECM) or plasma proteins ofthe host cell, are potential candidates for use as active component(s) for immunizing purposes.
This is illustrated by the vaccines based on M-like proteins mentioned above or disclosed in the literature, i. a. in WO 98/0561. The binding of fibrinogen and complement factor H to M-proteins is assumed to be important for the ability of streptococci to resist phagocytosis by polymorphonuclear leucocytes.
Another mechanism used by streptococci for attachment to host cells involves binding to the ECM component fibronectin (Fn) (3, 4). Binding between Fn-binding bacterial cell-surface proteins and immobilized Fn promotes internalization of streptococci by epithelial cells (1, 7, 11). Fibronectin is a dimeric glycoprotein found both in plasma and in a fibrillar form in the extracellular matrix. The main function of Fn is to mediate substrate adhesion of eukaryotic cells, which involves the binding of specific cell-surface receptors to certain domains ofthe Fn molecule (5). Furthermore, it also interacts with several other macromolecules, such as DNA, heparin, fibrin, and collagen (5).
Accordingly, several Fn-binding proteins from different streptococcal species have been cloned and sequenced previously. From S. equi, one Fn-binding protein has been cloned and characterized earlier, which is a Fn-binding cell-surface protein of subsp. zooepidemicus, that has been designated FNZ (9). Recently, a novel gene encoding a Fn-binding protein has been cloned from S. equi subsp. equi. The encoded protein, is clearly distinguishable from the previously isolated streptococcal Fn-binding proteins inclusive of the FNZ protein.
The present invention is based on this novel protein originally derived from S. equi subsp. equi and its potential use for immunization purposes. Generally, the present invention is directed to a protein having an amino acid sequence encoded by a nucleic acid sequence or gene, that forms a portion of the genome of S. equi subsp. equi, and which protein binds specifically to mammalian fibronectin.
The present invention is also directed to an isolated protein, specifically binding to fibronectin, such as mammalian, and specifically equine, fibronectin, and having an amino acid sequence as shown in SEQ. ID. NO. 1.
Moreover, the present invention is generally concerned with analogs or fragments of the present protein having fibronectin-binding properties. For instance, a suitable fragment is comprised ofthe sequence ofthe present protein, that lacks the N-terminal signal sequence of the preprotein. A further suitable fragment ofthe present protein lacks a portion of said amino acid sequence, said portion comprising an amino acid sequence binding to a collagen-binding domain of fibronectin.
The present invention is also concerned with methods to produce the present protein, analogs or fragments thereof, which methods are based on DNA technology; and with nucleic acid sequences, and more specifically DNA sequences or fragments, intended for use in 'such methods, as well as use of said protein, analogs or fragments thereof for therapeutic purposes, such as immunizing purposes.
The novel protein has been termed SFS, and, accordingly, the corresponding gene is designated sfs. For the purpose of convenience, these terms are frequently used in the description.
In the following, the present invention is disclosed more in detail with reference to the drawings, where
Fig. 1(A) shows a map of a clone designated pSFS62 with the gene sfs indicated.
Fig. 1 (B) shows a schematic presentation of protein SFS with the functional domains indicated. The bars correspond to the amino acid sequences of phagemid clones isolated by panning against Fn (S1-S4). Figures refer to the amino acid positions in protein SFS as shown in SEQ. ID. NO. 1 and the figures within brackets indicate the number of identical clones, that were isolated and sequenced.
Fig. 2 shows the results of Southern blot analysis of chromosomal DNA from ten streptococcal isolates. The DNA was digested by Apal and separated by pulsed-field gel electrophoresis in duplicate. The radioactively labeled probe used corresponds to the gene sfs. Lanes: 1, subsp. zooepidemicus ZV; 2, S. dysgalactiae S2; 3, S. equisimilis 172; 4, subsp. equi Bd 3221; 5, subsp. equi Bd 995; 6, subsp. zooepidemicus DSM 20727τ; 7, subsp. zooepidemicus ATCC 53698; 8, subsp. equi CCUG 1 1664; 9, subsp. equi NCTC 9682τ; 10, S. pyogenes AW43. Molecular weight marker (concatamers of lamda) is indicated to the left.
Fig. 3 shows the results from inhibition assays related to Fn-binding. Cells of subsp. zooepidemicus ZV, subsp. zooepidemicus DSM 20727, subsp. equi Bd3221, and subsp. equi 640 were incubated with iodine-labeled Fn (hatched bars) and with a mixture of iodine- labeled Fn and protein SFS-E (striped bars). The bars represent means of duplicates and the standard deviation is indicated.
Fig. 4 shows the results from inhibition assays related to inhibition of binding between collagen and Fn with protein SFS. Collagen type I coated micro titer wells were incubated with Fn and a two-fold serial dilution of SFS. Bound Fn was detected by antibodies as described in Example 3. Points represent means of duplicates and the standard deviation is indicated.
More specifically, the present invention is directed to a fibronectin-binding (hereinafter abbreviated Fn-binding) protein, which has an amino acid sequence that can be expressed from a nucleic acid coding sequence, that can be isolated from and forms a portion ofthe genomes of S. equi, for instance subsp. equi.
According to a suitable embodiment, the present invention is directed to an isolated protein, specifically binding to fibronectin and having an amino acid sequence as shown in SEQ. ID. NO. 1 below, or a fragment or analog thereof. SEQ. ID. NO. 1:
Met Arg Lys Thr Glu Gly Arg Phe Arg Thr Trp Lys Ser Lys Lys Gin 1 5 10 15 Trp Leu Phe Ala Gly Ala Val Val Thr Ser Leu Leu Leu Gly Ala Ala
20 25 30
Leu Val Phe Gly Gly Leu Leu Gly Ser Leu Gly Gly Ser Ser His Gin 35 40 45
Ala Arg Pro Lys Glu Gin Pro Val Ser Ser lie Gly Asp Asp Asp Lys 50 55 60
Ser His Lys Ser Ser Ser Asp Gin Pro Thr Asn His Gin His Gin Ala 65 70 75 80
Thr Ser Pro Ser Gin Pro Thr Ala Lys Ser Ser Gly His His Gly Asn 85 90 95
Gin Pro Gin Ser Leu Ser Val Asn Ser Gin Gly Asn Ser Ser Gly Gin 100 105 110
Ala Ser Glu Pro Gin Ala He Pro Asn Gin His His Gin Pro Gin Gly 115 120 125
Lys Pro Gin His Leu Asp Leu Gly Lys Asp Asn Ser Ser Pro Glr. Pro 130 135 140
Gin Pro Lys Pro Gin Gly Asn Ser Pro Lys Leu Pro Glu Lys Gly Leu 145 150 155 160
Asn Gly Glu Asn Gin Lys Glu Pro Glu Gin Gly Glu Arg Gly Leu Pro 165 170 175
Gly Leu Asn Gly Glu Asn Gin Lys Glu Pro Glu Gin Gly Glu Arg Gly 180 185 190
Glu Ala Gly Pro Pro Ser Thr Pro Asn Leu Glu Gly Asn Asn Arg Lys 195 200 205
Asn Pro Leu Lys Gly Leu Asp Gly Glu Asn Lys Pro Lys Glu Asp Leu 210 215 220
Asp Gly Tyr Asn His Gly Arg Arg Asp Gly Tyr Arg Val Gly Tyr Glu
225 230 235 240
Asp Gly Tyr Gly Gly Lys Lys His Lys Gly Asp Tyr Pro Lys Arg Phe 245 250 255
Asp Glu Ser Ser Pro Lys Glu Tyr Asn Asp Tyr Ser Gin Gly Tyr Asn 260 265 270 Asp Asn Tyr Gly Asn Gly Asn Pro Asp
275 280
The present invention is also related to proteins or polypeptides having an amino acid sequence as shown in SEQ. ID. NO. 1 containing deletions or substitutions of amino acids, such as fragments and analogs ofthe present protein having fibronectin-binding properties, suitably conserved, or specifically designed, Fn-binding properties. One such fragment or analog is comprised ofthe mature protein lacking the N-terminal amino acids no. 1 to 29 inclusive. Other fragments have en amino acid sequence corresponding to a portion ofthe amino acid sequence as shown in SEQ. ID. NO. 1 comprising a fibronectin-binding domain or an antigenic determinant or epitope. Still other fragments have an amino acid sequence corresponding to a portion ofthe sequence as shown in SEQ. ID. NO. 1, wherein an amino acid sequence binding to a collagen-binding domain of fibronectin (Fn) and comprising the amino acids QGERGEAGPP, is deleted.
A further embodiment is concerned with a protein of the present invention having an amino acid composition of approximately 53 glycine residues, 39 serine residues and 38 proline residues evenly distributed in the protein and optionally 13 tyrosine residues in the C- terminal part ofthe protein. Obviously, the present invention is concerned with a wild-type ptotein encoded by S. equi, that can be isolated and purified when recovered from said organism, as well as with a recombinant SFS protein as discussed above, said proteins having Fn-binding properties.
The present invention is also concerned with a nucleic acid sequence encoding the SFS protein or fragments or analogs thereof. Suitably, this sequence is a DNA sequence and contains an SFS coding sequence, such as the entire sfs gene, or a portion thereof encoding the SFS protein or a fragment or analog therof.
Accordingly, one embodiment of the present invention is related to a DNA sequence having a nucleotide sequence as shown in SEQ, ID. NO. 2 or to an equivalent thereof. SEQ. ID. NO. 2:
ATGAGAAAAA CAGAAGGACG TTTTCGCACA TGGAAGTCCA AAAAACAATG GCTATTTGCC 60
GGTGCAGTGG GAGCTGCACT TGTCTTTGGA GGTTTATTAG GAAGTCTTGG TGGCTCATCC 120
CAGCAGCCAG TCAGCTCGAT TGGAGATGAC GATAAGTCGC ACAAGAGCTC ATCACCACCG 180
AAAAAGGATA ACTTGCAGCC TAAGCCTTCA GATCAGCCTA CTAATCGCCC GTCCCAGCCG 240 ACAGCAAAGA GCTCAGGTCA TCATGGGAAT CAACCTCACC AAGGAAATAG TAGTGGACAG 300
GCCTCAGAGC CTCAGGCTAT TCCTAATCAA GGGCTGAGAG GAGGTAACAG CTCTGGTTCA 360
GGTCATCACC ATCAGCCACA AGATCTAGGT AAGGATAATT CTAGCCCGCA GCCTCAACCA 420
AAGCCTCAGG GCAAAAAAGG CTTGAATGGT GAAAATCAGA AGGAACCGGA GCAAGGTGAA 480
CGAGGTTCAG GGTTGAGTGG TAATAATCAA GGCCGTCCTT CGCTTCCAGG CTTGAATGCA 540 GAGCAAGGTG AACGAGGTGA AGCCGGTCCC CCATCAACTC CGAATTTAGA TCCTTTAAAA 600
GGATTAGATG GAGAGAATAA GCCAAAGGAA GATTTAGACG GTAATGATGA ATCACCAAAA 660
CTTAAAGACG AACACCCCTA CAATCATGGT CGTCGCTATG AGGATGGATA TGGTGGCAAA 720
AAGCACAAAG GAGATTATCC TAAGCGAAAG GAATATAATG ACTATAGTCA AGGGTATAAT 780
GATAATTATG GAAATGGCGA TAGAGGTGGT AAGAGAGGAT ACGGCTATTC TTACAATCCC 840 GACTAA 846
The present invention is also related DNA sequences having nucleotide substitutions, that do not change the encoded product or interfere with its expression. This is due to the well-known redundancy of the genetic code, i. e. more than one coding nucleotide triplet (codon) can code for or define a particular amino acid residue or a function, such as a stop codon function, etc.. Thus, such functionally equivalent sequences are also encompassed by the present invention. Such equivalents may also arise due to spontaneous mutations.
Accordingly, when used to produce the present protein, such as a protein having the amino acid sequence shown in SEQ. ID. NO. 1, with methods based on recombinant DNA technology, the above DNA sequence may be modified to adapt to the codon frequency of the host organism used to produce the present protein, or fragments or analogs thereof.
The present invention is also concerned with a host cell comprising a DNA fragment or sequence of the present invention, e. g. a eukaryotic or, suitably, a prokaryotic host cell. A suitable prokaryotic host cell is derived from different strains of E. coli.
Furthermore, the present invention is concerned with a method to produce the present protein, fragments or analogs thereof comprising culturing a host cell containing the DNA sequence of the present invention, and isolating the expressed protein from the culture. Suitably this method also comprises purification of the expression product, such as affinity chromatography purification, conveniently based on use of "affinity tails".
Thus, a suitable method comprises
(a) introducing a DNA fragment ofthe present invention into an expression vector;
(b) introducing the said vector, which contains the said DNA fragment, into a compatible host cell;
(c) culturing the host cell provided in step (b) under conditions required for expression ofthe product encoded by said DNA fragment; and
(d) isolating the expressed product from the cultured host cell.
Preferably, said method further comprises a step (e), wherein the isolated product from step (d) is purified, e. g. by affinity chromatography, such as Fn-affϊnity chromatography, or with the use of "affinity tails" as is well-known in this field of art.
The present invention is further concerned with a vaccine comprising the present Fn- binding protein or a fragment or an analog thereof as an antigenic or immunogenic component. This vaccine is intended for use as a vaccine protecting against infection with any one ofthe two subspecies equi and zooepidemicus of S. equi.
A further embodiment ofthe present invention is concerned with a vaccine as defined above, that protects horses against strangles caused by S. equi subsp. equi infection. Suitably, such a vaccine could protect also against infection with subsp. zooepidemicus.
The vaccine ofthe present invention is suitably a subunit vaccine. Moreover, the vaccine may be comprised of a cocktail of antigenic and /and or immunogenic components comprising the present protein or an analog or a fragment thereof as one such component.
The present invention is also concerned with use ofthe present Fn-binding protein, analogs or fragments thereof in the preparation of a vaccine protecting against S. equi, for instance a vaccine as disclosed above. Furthermore, the present invention is also concerned with the production of antibodies raised against the present protein , analogs or fragments thereof, with fragments of such antibodies and with the production of antisera. Antibodies and/or antisera could be produced by in vivo administration, e. g. injection, of an antigen comprising the said protein, an analog or a fragment thereof, to a host to elicit an immune response in said host, and recovering antiserum thereby produced in said host and, optionally, recovering or isolating antibodies contained in said antiserum or in other body fluids from said host. Not only polyclonal but also monoclonal antibodies could be produced in accordance with well-known methods. EXPERIMENTAL PART
Bacterial strains, plasmids, and growth conditions. Ninety-eight clinical isolates of S. equi (50 isolates of subsp. equi strains and 48 isolates of subsp. zooepidemicus strains) collected from different parts of Sweden between 1982-1996 were together with the streptococcal control strains S. dysgalactiae S2 and S. equisimilis 172 obtained from the National Veterinary Institute, Uppsala. The S. pyogenes strain AW-43 was a kind gift from Dr G. Lindahl, Lund University. The plasmid pUC 19 was used for cloning purposes and pGEX- 5X-2 (Pharmacia Biotech, Uppsala, Sweden) for facilitating purification of proteins. Phagemid pG8SAET (19) was used for purification of protein SFS and for construction ofthe phage display library. Streptococcal strains were grown on horse blood agar plates or in Todd- Hewitt broth (Oxoid, Basingstoke, UK) supplemented with 0.5% yeast extract (THY). E. coli strains were cultured in Luria-Bertani (LB) medium supplemented in appropriate cases with 50 μg of ampicillin per ml.
As regards the isolates of S. equi, it is known that isolates of subsp. equi are serologically and genetically very homogeneous whereas isolates of subsp. zooepidemicus display a high degree of heterogeneity (2, 8, 10, 13).
Example 1. Cloning and isolation of a gene sfs encoding the Fn-binding protein SFS.
A. Construction of a phagemid library. A shotgun phage display library was constructed from subsp. equi Bd 3221 essentially as described by Jacobsson and Frykberg (6). Briefly, chromosomal DNA of this strain was isolated as described earlier (9) and subsequently purified and fragmented by sonication.
The obtained fragments were treated with T4 DNA polymerase to generate blunt ends and subsequently ligated into S«αBI-digested and dephosphorylated pG8SAET vector. Approximately 4.5 x 106 ampicillin-resistant transformants were obtained after electrotransformation of the ligated material into E. coli, TGI cells.
Twenty randomly picked transformants were all shown to contain inserts. Cells from an overnight culture ofthe transformants were infected with helper phage R408 and poured together with soft agar onto LA + ampicillin plates (LB medium supplemented with 1.5 % agar and 50 μg ampicillin/ml) and incubated overnight. Phage particles were eluted from the soft agar by addition of LB and vigorous shaking. The suspension was centrifugated and the supernatant sterile filtrated. The titer of the library was determined to 7 x 1010 CFU/ml.
This library was used in the following Section B, wherein phage particles containing inserts related to Fn-binding properties are identified.
B. Panning of the phagemid library. Microtiter wells (Maxisorp, Nunc, Copenhagen, Denmark) were coated with human Fn (Sigma, St. Louis, MO) at a concentration of 100 μg/ml in 50 mM sodium carbonate, pH 9.7. The wells were blocked with PBS-0.05% Tween 20 (PBS-T) containing casein (O.lmg/ml). After washing the wells with PBS-T, the library from Section A above was added to the wells. Thereafter, the wells were extensively washed with PBS-T and then eluted with 140 mM NaCl, 50 mM Na-citrate (pH 2.0).
To obtain transformed cells containing the Fn-binding insert, eluate was collected, neutralized, infected with E .coli TGI cells and spread on LA plates containing ampicillin.
Next day, approximately 1,500 colonies were pooled and after infection with helper phage R408 the sample was mixed with soft agar and poured out on LA plates. After incubation overnight, the phagemid particles were extracted and subjected to another round of panning.
After the first panning, 41 % ofthe colonies were found to bind Fn and after the second panning all 180 colonies were positive for Fn-binding.
C. Screening for Fn-binding clones containing an insert encoding SFS. In this section, the gene encoding the novel Fn-binding protein SFS was screened for based on the knowledge that the previously disclosedy z gene isolated from subspecies zooepidemicus and encoding the Fn-binding protein FNZ is present also in the genome of subspecies equi . Thus, a negative screening test was used, wherein cells containing inserts related to Fn-binding, i. e. cells positive when screening with a rabbit anti-Fn antibody, but not containing inserts related to Fn-binding of FNZ, i. e. those ofthe positive cells that were negative when the fnz gene is used as a screening probe, were selected and presumed to contain SFS-related inserts. From each panning performed in section B, 180 colonies were transferred in triplicate to LA plates and incubated overnight. The following day, one plate was stored (masterplate) and the colonies from the two remaining plates were transferred to nitrocellulosa filters and incubated for two hours.
Cells from one filter were lysed using chloroform vapor and after blocking the filter with PBS-T supplemented with casein (O.lmg/ml), it was incubated with human Fn (lμg/ml; Sigma) for 2 h, and after washing, a rabbit anti-Fn antibody (diluted 1/1000; Sigma) was added. After 1 h of incubation and washing, the filter was incubated for additional 1 h with a HRP-labeled secondary antibody (diluted 1/1000; Bio-Rad, Richmond, Calif). Reactive bands were visualized by using 4-chloro-l-naphthol (Serva, Heidelberg, Germany).
The second filter was subjected to colony hybridization essentially as described in Sambrook et al. (22) with use of a radioactively labeled probe that covered the entire fnz gene and was generated by PCR amplification of chromosomal DNA from subsp. zooepidemicus strain ZV using the primers:
5-fnz, 5'-CGGGATCCCTATTACACATTCTCATCTCATAT (positions 19-42) and 3-fnz, 5'-GGAATTCCAGAAAGCCCGCCTGTAAAC (positions 1954-1935). The indicated positions in the respective primers correspond to the published ■ sequence ofthe gene fnz (9).
In these colony hybridization tests, 41 % of Fn-binding clones from the first panning and 30 % from the second panning hybridized against the^z gene from subsp. zooepidemicus ZV used as a probe. D. Cloning and isolation of the gene sfs. Clones from Section C, displaying Fn- binding activity but negative in the colony hybridization assay, were selected as candidate sfs- gene-containing clones. Accordingly, these clones were sequenced using thermo sequence dye terminator cycle sequencing pre-mix kit (Amersham) and the ABI Model 377XL DNA sequencer. Computer programs from the PCGENE, DNA, and protein sequence analysis software package (Intelligenetics, Inc., Mountain View, Calif.) were used to record and analyze the sequence data.
Altogether, eleven Fn-binding but fnz negative clones were analyzed and found to contain inserts identical to one of four different types of inserts, all with overlapping sequences and an open reading frame. These four different phagemid clones designated S1-S4 are shown in Fig IB. Based on the overlapping sequences, primers were designed and used to generate a probe consisting ofthe complete sfs gene using PCR amplification as disclosed in the section concerned with Southern blots below.
To isolate the complete gene encoding the Fn-binding activity, Southern blot analysis of restriction enzyme digested chromosomal DNA of subsp. equi Bd 3221 was performed as disclosed below and revealed that a 2.6 kb Sspl fragment contained sfs. Accordingly, fragments of this size were purified from a preparative agarose gel and ligated into pUC19. The ligation mix was electroporated into E. coli and transformants were screened for Fn- binding activity as described above. Among several positive clones one, designated pSFS62, was selected and the insert sequenced.
This clone, pSFS62, had an open reading frame of 1,035 bp, from which the phagemid sequences were found to originate (Figs. 1 and SEQ. ID. NO. 2). The open reading frame is preceded by sequences typical for promoter and ribosome-binding sites (not shown) and is followed by sequences (not shown) resembling a transcriptional termination, suggesting that the gene is translated from a monocistronic messenger. The SFS-coding nucleotide sequence ofthe sfs gene is shown in SEQ. ID. NO. 2.
Southern blots. The Southern blot analysis referred to above and further below, was performed according to the following. Agarose imbedded chromosomal DNA digested with Apal was resolved on 1.2% SeaKem GTG agarose gel (FMC, Rockland, ME) in 0.5 x TBE buffer by PFGE using a Gene Navigator (Pharmacia Biotech, Uppsala, Sweden) as earlier described (10). The DNA was transferred to nylon filters (Hybond-N+, Amersham) by vacuum blotting (VacuGene XL, Pharmacia Biotech) in accordance with the manufacturer's protocol. After cross-linking, the filters were prehybridized for 2 h at 65 °C in 6 x SSC, 3 x Denhardt's solution, and 0.5% SDS and subsequently incubated with the radioactively labeled sfs probe overnight, using the same conditions. The membranes were washed 3 x 20 min at 65°C with 0.2 x SSC, 0.1% SDS and subjected to autoradiography.
The probe sfs was generated by PCR amplification of chromosomal DNA from subsp. equi Bd 3221 using the primers: fs5, 5'-ACAAGCCATGGAGCACTTGTCTTTGGAGGT and fr4, 5'-GTCGGGATTGTAAGAATAGCC.
The single band obtained after agarose gel electrophoresis was purified and random- primed.
Example 2. Construction and purification of SFS as a fusion protein. The purified PCR-fragment from Example 1 encoding the mature protein of SFS, and described under Southern blots in Example 1, Section D, was digested with Ncol and ligated into SnaBl- Ncol opened pG8SAET. This vector encodes a 13 amino acid peptide tag (E-tag) which facilitates the purification ofthe recombinant protein using a HiTrap Anti-E tag column (Pharmacia Biotech). The recombinant protein SFS-E was purified from the periplasmic space according to the manufacturer's protocol. After cleaving from the E-tag, the SFS protein was obtained having a calculated molecular mass of 40 kDa. The charged amino acids, followed by a stretch of hydrophobic residues in the N-terminal end of the protein, indicate a signal sequence and by the method of von Heijne (14) a possible signal sequence cleavage site was found between amino acids 29 and 30, resulting in a mature protein with a calculated molecular mass of 36 kDa. The isolated Fn-binding phagemid clones contained inserts originating from the central part of the protein, where two repetitive sequences of 21 residues, called Rl and R2, resp., are situated (Fig. 1). Three amino acids were found to dominate the composition of protein SFS, 53 residues are glycines (14.4%), 39 serines (10.6%), and 38 prolines (10.3%). These three amino acids are evenly distributed in the protein in contrast to the 13 tyrosine residues which occur only in the C-terminal part ofthe protein. Protein SFS does not contain any sequence motifs known to mediate attachment to the bacterial cell-wall.
Example 3. Inhibition assays. Cells from overnight cultures of streptococci were collected by centrifugation, washed in PBS, and suspended in PBS-0.2% Tween 20 to an optical density at 600 nm of 0.2. In cases of inhibition, 25 nM of affinity purified fusion- protein SFS-E was preincubated 15 min with 16 pM of 12DI-labeled human Fn (91,061 cpm) and thereafter bacteria (500 μl) were added. After two hours incubation at room temperature, the mixtures were centrifuged and the supernatants removed. The radioactivity associated with the pellets was quantified in a gamma counter (LKB Wallac, Turku, Finland). Radioactivity (808 cpm) recovered from a control (tubes that contained no streptococci) was subtracted from each test.
Example 4. Expression of the sfs gene. RNA was extracted from S. equi cells by using the Blue FastRNA kit (Bio 101, Vista, CA) according to the manufacturer's protocol. RNA concentration was determined spectrophotometrically and by visual estimation ofthe rRNA bands on an agarose gel. RNA (10 μg) was loaded on a formaldehyde-containing agarose gel. RNA was transferred by vacuum-blotting to a positively charged nylon filter (Hybond-N+, Amersham) and cross-linked. Further steps were performed as described for Southern blots above with the exception that ssDNA was added to the pre-hybridization and hybridization solutions. Example 5. The ability of SFS to inhibit the binding between collagen and Fn.
For the enzyme-linked immunosorbent assay (ELISA), polystyrene 96-well microtiter plates were coated for one hour with collagen type I from calf skin (Boehringer, Mannheim, Germany) in PBS. The wells were blocked for one hour with PBS-T supplemented with casein (0.1 mg/ml) and then washed four times with PBS-T. The fusion protein SFS-E was diluted in a two-fold serial and added to the wells together with 0.2 ng of Fn. After 2 h incubation, the wells were washed and a rabbit anti-Fn antibody was added and allowed to bind for 1 h. Finally, the wells were incubated for 1 h with a secondary HRP-labeled antibody. After washing, bound material was quantified by using tetramethylbenzidine (Boehringer) and a microplate reader (Bio-Tek Instruments, Vinooski, VT). Measurement was done at a wavelength of 450 nm. Absorbancy in wells without added fusion protein was set to 100 % and absorbancy in wells where Fn had been excluded was set to 0 %.
RESULTS
I. The gene sfs is generally present in isolates of subsp. equi. Southern blots performed as disclosed above revealed that a [ P] dATP-labeled probe, corresponding to the gene sfs, hybridized to all the 50 subsp. equi and to 41 out of 48 subsp. zooepidemicus isolates tested. The results from the hybridization analysis are, for a selected number of strains, shown in Fig. 2. No significantly weak signal, that could not be explained by less chromosomal DNA on the gel, was detected for any ofthe positive S. equi isolates. The seven isolates of subsp. zooepidemicus that were sfs negative could not be related to each other, considering symptoms, temporal, and geographical origin. Furthermore, the seven negative isolates were obtained from different species, horses (n = 4), cows (n = 2), and dog (n = 1). The sfs probe did not hybridize to any of the three control strains of other streptococcal species (Fig. 2).
II. Protein SFS displays sequence similarity to both collagen and a potential cell- wall protein of S. pyogenes. Collagen sequences gave highest scores when searching the database Swissprot for SFS-like sequences. The similarity was evenly distributed through protein SFS, and the main reason for the high score is the high content of glycine, serine, and proline, i. e. residues which are also common in collagen. However, a more pronounced similarity was seen for the Fn-binding domain of SFS against collagen. A sequence comparison was also done against the Oklahoma S. pyogenes genomic sequence database, which at the time of search consisted of 98% ofthe S. pyogenes genome. SFS aligned best against a database sequence which besides high content of glycine and proline residues also displayed the motif QGERGETGP. Eight of these nine residues are present in the Fn-binding domain of SFS. Similar motifs are also present in chains of collagen. Alignment of these sequences are shown in the following Table I. At a closer study ofthe aligned S. pyogenes sequence, it was found that the aligned motif is situated in the middle of a potential gene, encoding a typical streptococcal cell-surface protein. This statement is based on the following: (i) promoter sequences and a putative ribosome-binding site are present adjacent to an open reading frame, (ii) in the C-terminal part there is a proline-rich domain with the cell-wall anchoring motif LPXTGX, (iii) the LPXTGX motif is directly followed by a stretch of 23 hydrophobic residues and the open reading frame is terminated by six residues whereof three are charged, and (iv) a potential hairpin loop is situated 38 bp downstream the stop codon. However, a start codon in an acceptable distance to the ribosome binding site could not be found.
Table I
SFS QGERGEAGPP
S. pyogenes QGERGETGPA Collagen α2 (I) 711 PGERGEVGPA Collagen αl (1) 991 SGERGPPGPM Collagen αl (II) 329 PGERGRTGPA Collagen αl (III) 797 PGERGETGPP Collagen αl (IV) 319 QGEKGEAGPP
In this table, alignment of amino acid sequences from different types of collagen and the potential cell-surface protein from S pyogenes to a motif present in the Fn-binding domain of SFS is illustrated. The figures indicate the number ofthe first amino acid from the collagen sequences. Bold letters indicate identical residue to the SFS motif.
III. Inhibition of binding between Fn and cells of S. equi. Recombinant protein SFS was purified by using affinity tails and the purified protein was found to bind Fn in a Western blot assay (data not shown). Before adding iodinated Fn to cells of S. equi the labeled Fn was, in appropriate cases, preincubated with SFS in a molar ratio of 1 :1,500. After incubation the cells were collected by centrifugation and after removing the supernatant, the radioactivity bound to the pellets was measured. From the results from the inhibition experiments shown in Fig. 3 it is evident that the protein SFS has, for both subspecies, an inhibitory effect, although the two subsp. equi strains bind considerable less Fn compared to the two subsp. zooepidemicus strains
IN. Protein SFS inhibits the binding between Fn and collagen. The similarity between protein SFS and collagen suggested that these proteins might bind to the same site on the Fn molecule. In order to investigate this, microtiter wells coated with collagen were incubated with a mixture of Fn and a serial dilution of protein SFS. Bound Fn was detected by an anti-Fn antibody and as seen in Fig. 4, protein SFS inhibits the binding in a concentration dependent way. In a similar assay, the previously known protein FΝZ did not inhibit the binding between Fn and collagen (data not shown). Furthermore, protein SFS did not inhibit the binding between the said protein FNZ and Fn, and the protein FNZ did not inhibit the binding between protein SFS and Fn. Protein SFS does not bind collagen. This was tested in order to control that the inhibition of binding between Fn and collagen by protein SFS is dependent on the binding of protein SFS to Fn and not to collagen. Taken together this suggests that protein SFS and the previously known protein FNZ have clearly separate binding sites on the Fn molecule and that protein SFS binds to the 30-40 kDa collagen- binding domain of Fn.
In the following Example 6, the potential use of the present protein as a vaccine is illustrated in a test wherein the immunogenic properties of the present novel protein are confirmed.
Example 6. Immunogenic properties of Protein SFS. Affinity purified recombinant protein SFS (Example 2) was, under reducing conditions, subjected to SDS- PAGE on a precasted 8-25 % gradient-gel using the PHAST system (Pharmacia Biotech, Sweden). The molecular weight markers used were obtained from BioRad, CA, USA. After electrophoresis was completed, a nitrocellulose (NC) filter (Hybond C, Amersham, UK) previously soaked in PBS was put on the gel and the temperature raised to 45° C. After 45 minutes, the NC-filter was wetted with 1 ml PBS, and removed and placed in 15 ml PBS-T containing casein (0.1 mg/ml) for 1 hour (with two changes of PBS-T casein solution) at room temperature under gentle agitation. The gradient-gel was after transfer removed and stained with Coomassie-blue using the PHAST system. The NC-filter was removed and incubated in 5 ml PBS-T casein solution containing 5 μl serum from a horse which previously had got the diagnosis strangles and found to be a carrier of S. equi. After 2 hours incubation at room temperature, under gentle agitation, the filter was extensively washed with PBS-T and incubated in 5 ml PBS-T casein solution containing rabbit anti horse antibodies (Nordic Immunology,
Netherlands) at a dilution of 1: 1000. After 1 hour of incubation at room temperature, under gentle agitation, the filter was extensively washed with PBS-T and incubated in 5 ml PBS-T casein solution containing horseradish peroxidase labeled goat anti rabbit IgG (BioRad) at a dilution of 1: 1000. After 1 hour of incubation at room temperature, under gentle agitation, the filter was extensively washed with PBS-T and PBS.
To visualize the bound IgG conjugate, the filter was transferred to a solution containing a substrate for peroxidase (containing 25 ml PBS + 6ml 4-chloro-l-naphtol (Sigma, USA, 3 mg/ml in methanol) + 20 μl H2O2 (35%). After about 15 minutes, the degree of color was measured by eye. The bands appearing on the NC-filter and the bands appearing on the corresponding Coomassie-blue stained PAGE were compared.
The obtained results clearly showed that (i) the recombinant produced SFS protein was recognized by antibodies present in the serum from the horse with strangles, and (ii) no bands were seen on the NC-filter in the lane with the different molecular weight markers. Thus, this means that protein SFS is expressed by S. equi during the infection process and that this protein is immunogenic
REFERENCES
1. Cue, D., P. E. Dombek, H. Lam, and P. P. Cleary. 1998. Streptococcus pyogenes serotype Ml encodes multiple pathways for entry into human epithelial cells. Infect.
Immun. 66:4593-4601.
2. Galan, J. E., and J. F. Timoney. 1988. Immunologic and genetic comparison of streptococcus equi isolates from the united states and europe. J. Clin. Microbiol. 26:1142-1146. 3. Hanski, E., and M. G. Caparon. 1992. Protein F, a fibronectin-binding protein, is an adhesin ofthe group A streptococcus Streptococcus pyogenes. Proc. Natl. Acad. Sci. USA 89:6172-6176.
4. Hanski, E., P. A. Horwitz, and M. G. Caparon. 1992. Expression of protein F, the Fibronectin-binding protein of Streptococcus pyogenes JRS4, in heterologous streptococcal and enterococcal strains promotes their adherence to respiratory epithelial cells. Infect. Immun. 60:5119-5125.
5. Hynes, R. O. 1990. Fibronectins. Springer Verlag, New York.
6. Jacobsson, K., and L. Frykberg. 1996. Phage display shot-gun cloning of ligand- binding domains of procaryotic receptors approaches 100% correct clones. BioTechniques 20: 1070- 1081.
7. Jadoun, J., V. Ozeri, E. Burstein, E. Skutelsky, E. Hanski, and S. Sela. 1998. Protein FI is required for efficient entry of Streptococcus pyogenes into epithelial cells. J. Infect. Dis. 178: 147-158
8. Jorm, L. R., D. N. Love, G. D. Bailey, G. M. Bailey, and D. A. Briscoe. 1994. Genetic structure of populations of β-haemolytic Lancefield group C streptococci from horses and their association with disease. Res. Vet. Sci. 57:292-299.
9. Lindmark, H., K. Jacobsson, L. Frykberg, and B. Guss. 1996. Fibronectin- binding protein of Streptococcus equi subsp. zooepidemicus. Infect. Immun. 64:3993-3999. 10. Lindmark, H., P. Jonsson, E. Olsson Engvall, and B. Guss. 1998. Pulsed-field gel electrophoresis and distribution of the genes zag and fnz in isolates of streptococcus equi. In Press. 11. Molinari, G., S. R. Talay, P. Valentin-Weigand, M. Rohde, and G. S. Chhatwal.
1997. The fibronectin-binding protein of Streptococcus pyogenes Sfbl, is involved in the internalization of group A streptococci by epithelial cells. Infect. Immun. 65:1357-1363.
12. Nilsson, M., L. Frykberg, J. I. Flock, L. Pei, M. Lindberg, and B. Guss. 1998. A fibrinogen-binding protein of Stαphylococcus epidermidis. Infect. Immun. 66:2666-2673.
13. Skjold, S. A., P. G. Quie, L. A- Fries, M. Barnham, and P. P. Cleary. 1987. DNA fingerprinting of streptococcus zooepidemicus (Lancefield group C) as an aid to epidemiological study. J. Infect. Dis. 155:1145-1150.
14. von Heijne, G. 1986. A new method for predicting signal sequence cleavage sites. Nucleic Acids Res 14:4683-4690.
Nucleotide Sequence Accession Number: The nucleotide sequence of
Figure imgf000019_0001
gene (9) is available from the EMBL sequence data bank under accession number X99995. The complete gene sequence and the deduced amino acid sequence ofthe protein FNZ are shown below:
17A
o • -r O -» rt 85 σ -• r- e* an
Figure imgf000020_0001
17B
Figure imgf000021_0001

Claims

18CLAIMS
1. A protein having an amino acid sequence encoded by a nucleic acid sequence , that can be isolated from and forms a portion ofthe genomes of S. equi, and which protein can be expressed from said nucleic acid sequence and binds specifically to mammal fibronectin, or an analog or fragment of said protein.
2. An isolated protein specifically binding to fibronectin and having an amino acid sequence as shown in SEQ. ID. NO. 1, or an analog or fragment thereof.
3. The protein of claim 2 having an amino acid sequence as shown in SEQ. ID. NO. 1 containing deletions or substitutions of amino acids.
4. The protein of claim 2, wherein the protein is a fragment comprised ofthe amino acid sequence of SEQ. ID. NO. 1 that lacks an N-terminal sequence, suitably amino acids no
1-19 inclusive in the sequence of SEQ. ID. NO. 1.
5. The protein of claim 3, which has an amino acid sequence corresponding to a portion ofthe sequence as shown in SEQ. ID. NO. 1 wherein an amino acid sequence binding to a collagen-binding domain of fibronectin (Fn) and comprising the sequence consisting of amino acids QGERGEAGPP, is deleted.
6. The protein of claim 1, wherein the protein has an amino acid composition of approximately 53 glycine residues, 39 serine residues and 38 proline residues evenly distributed in the protein and optionally 13 tyrosine residues in the C-terminal part ofthe protein.
7. A DNA fragment comprising a nucleotide sequence coding for a protein according to any one of claims 1-6.
8. The DNA fragment of claim 7, wherein said fragment has a nucleotide sequence as shown in SEQ, ID. NO. 2 or an equivalent thereof.
9. A recombinant DNA molecule comprising a replicable vector, which suitably is an expression vector, and a DNA fragment according to claim 7 or 8 inserted therein.
10. A host cell comprising a DNA fragment in accordance with claim 7 or 8,or the recombinant DNA molecule of claim 9.
11. The host cell of claim 10, wherein said cell is a prokaryotic host cell, suitably a prokaryotic host cell comprised of a strain of E. coli.
12. A method of producing the protein of any one of claims 1-6, or fragments or analogs thereof comprising culturing a host cell as defined in claim 10 or 1 1, and isolating the expression product comprising the protein from the culture.
13. The method of claim 12, wherein said method further comprises purification of the expression product, such as by affinity chromatography.
14. The method of claim 12, which method comprises
(a) introducing the DNA fragment encoding the protein or fragment or analog thereof into an expression vector;
(b) introducing the said vector, which contains the said DNA fragment, into a compatible host cell;
(c) culturing the host cell provided in step (b) under conditions required for expression ofthe product encoded by said DNA fragment; and
(d) isolating the expressed product from the cultured host cell, and, optionally,
(e) purifying the isolated product from step (d) by affinity chromatography or other chromato graphic methods known in the art.
15. A vaccine comprising the fibronectin-binding protein or a fragment or an analog thereof as defined in any one of claims 1-6 or as produced by a method as defined in any one of claims 12-14.
16. The vaccine of claim 15, which vaccine is a vaccine that protects horses against strangles caused by S. equi infection.
17. Use of a fibronectin-binding protein, analogs or fragments thereof in the preparation of a vaccine protecting against S. equi infection inclusive of strangles caused by subsp. equi infection in horses.
18. An antibody specific for a fibronectin-binding protein of any one of claims 1-6 or a fragment or an analog thereof, which antibody is polyclonal or monoclonal, or a fragment of said antibody.
19. An antigenic preparation comprising an antigen consisting ofthe protein of any one of claims 1-6 or a fragment or an analog thereof.
20. An antiserum comprising an antibody of claim 18, which is comprised of a polyclonal antibody.
21. A method for the production of an antiserum, said method comprising administering an antigenic preparation of claim 19 to an animal host to produce antibodies in said animal host and recovering antiserum containing said antibodies produced in said host animal. 20
22. A method of prophylactic or therapeutic treatment of S. equi infection in mammals, suitably horses, comprising administering an immunologically effective amount of a vaccine of claim 15 or 16, an antibody of claim 18, or an antiserum of claim 20.
PCT/SE1999/002448 1998-12-22 1999-12-21 Novel fibronectin-binding protein WO2000037496A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP99964919A EP1151003A1 (en) 1998-12-22 1999-12-21 Novel fibronectin-binding protein
AU30947/00A AU3094700A (en) 1998-12-22 1999-12-21 Novel fibronectin-binding protein
CA002355831A CA2355831A1 (en) 1998-12-22 1999-12-21 Novel fibronectin-binding protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9804491-0 1998-12-22
SE9804491A SE9804491D0 (en) 1998-12-22 1998-12-22 Novel fibronectin binding protein

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09600720 A-371-Of-International 2000-09-20
US10/269,017 Continuation US20030165527A1 (en) 1998-12-22 2002-10-11 Novel fibronectin-binding protein

Publications (1)

Publication Number Publication Date
WO2000037496A1 true WO2000037496A1 (en) 2000-06-29

Family

ID=20413813

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1999/002448 WO2000037496A1 (en) 1998-12-22 1999-12-21 Novel fibronectin-binding protein

Country Status (5)

Country Link
EP (1) EP1151003A1 (en)
AU (1) AU3094700A (en)
CA (1) CA2355831A1 (en)
SE (1) SE9804491D0 (en)
WO (1) WO2000037496A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004032957A1 (en) 2002-10-11 2004-04-22 Bengt Guss Immunization of non-human mammals against streptococcus equi
US6777547B1 (en) * 2000-01-31 2004-08-17 Andreas Podbielski Collagen-binding proteins from streptococcus pyogenes
WO2009075646A1 (en) 2007-12-13 2009-06-18 Bengt Guss Improved immunizing composition
WO2011149419A1 (en) 2010-05-26 2011-12-01 Intervacc Ab Vaccine against streptococcal infections based on recombinant proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031389A2 (en) * 1997-01-21 1998-07-23 The Texas A & M University System Fibronectin binding protein compositions, antibodies thereto, and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031389A2 (en) * 1997-01-21 1998-07-23 The Texas A & M University System Fibronectin binding protein compositions, antibodies thereto, and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HANS LINDMARK ET AL.: "Fibronectin-Binding Protein of Streptococcus equi subsp. Zooepidemicus", INFECTION AND IMMUNITY, vol. 64, no. 10, 1996, pages 3993 - 3999, XP002926630 *
HANS LINDMARK ET AL.: "SFS, a Novel Fibronectin-Binding Protein from Streptococcus equi, Inhibits the Binding between Fibronectin and Collagen", INFECTION AND IMMUNITY, vol. 67, no. 5, May 1999 (1999-05-01), pages 2383 - 2388, XP000906770 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777547B1 (en) * 2000-01-31 2004-08-17 Andreas Podbielski Collagen-binding proteins from streptococcus pyogenes
WO2004032957A1 (en) 2002-10-11 2004-04-22 Bengt Guss Immunization of non-human mammals against streptococcus equi
US8404245B2 (en) 2002-10-11 2013-03-26 Intervacc Ab Immunization of non-human mammals against Streptococcus equi
WO2009075646A1 (en) 2007-12-13 2009-06-18 Bengt Guss Improved immunizing composition
US9987342B2 (en) 2007-12-13 2018-06-05 Intervacc Ab Immunizing composition
WO2011149419A1 (en) 2010-05-26 2011-12-01 Intervacc Ab Vaccine against streptococcal infections based on recombinant proteins
US9333252B2 (en) 2010-05-26 2016-05-10 Intervacc Ab Vaccine against streptococcal infections based on recombinant proteins
EP3135684A1 (en) 2010-05-26 2017-03-01 Intervacc AB Vaccine against streptococcal infections based on recombinant proteins
US9795664B2 (en) 2010-05-26 2017-10-24 Intervacc Ab Vaccine against streptococcal infections based on recombinant proteins

Also Published As

Publication number Publication date
AU3094700A (en) 2000-07-12
CA2355831A1 (en) 2000-06-29
EP1151003A1 (en) 2001-11-07
SE9804491D0 (en) 1998-12-22

Similar Documents

Publication Publication Date Title
KR101078919B1 (en) Novel Streptococcus antigens
EP1456231A2 (en) Streptococcus antigens
DK2450054T3 (en) New virulence factors of Streptococcus pneumoniae
CN101313068A (en) Streptococcus suis polypeptides and polynucleotides encoding same and their use in vaccinal and diagnostic applications
CA2417357A1 (en) Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof
JP2001503609A (en) A novel fibrinogen-binding protein derived from coagulase-negative staphylococci
US7419672B2 (en) Genes and proteins, and their use
US6669940B2 (en) Recombinant fusobacterium necrophorum leukotoxin vaccine and preparation thereof
WO2004020609A9 (en) Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection
AU758764B2 (en) Epitope peptides immunogenic against (streptococcus pneumoniae)
EP1151003A1 (en) Novel fibronectin-binding protein
WO2002061070A2 (en) Environmentally regulated genes, involved in the virulence of streptococcus suis
JP2001505534A (en) Treatment and diagnosis of Gram-positive bacterial infections
AU2001259138B2 (en) Recombinant fusobacterium necrophorum leukotoxin vaccine and preparation thereof
AU771376B2 (en) Lawsonia derived gene and related FlgE polypeptides, peptides and proteins and their uses
US20030165527A1 (en) Novel fibronectin-binding protein
AU2001259138A1 (en) Recombinant fusobacterium necrophorum leukotoxin vaccine and preparation thereof
US20030054009A1 (en) Clostridium difficile vaccine
AU758555B2 (en) Peptides
KR20080052693A (en) Genes, Proteins and Their Uses
JP2001504335A (en) Lactoferrin-binding protein of Streptococcus uberis
BRAMBILA et al. Two outer membrane lipoproteins from histophilus somni are Immunogenic in rabbits and sheep and induce protection against bacterial challenge in mice
WO2002072623A1 (en) Genes and proteins, and their use
WO2008127102A1 (en) S. pnuemoniae transcytosis protein
KR19990022600A (en) Helicobacter pyrroli related nucleic acid and amino acid sequences for diagnosis and treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09600720

Country of ref document: US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2355831

Country of ref document: CA

Ref country code: CA

Ref document number: 2355831

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 512540

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 30947/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999964919

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999964919

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999964919

Country of ref document: EP